Frontiers in Psychiatry (Nov 2018)
Effect of Betahistine and Metformin on Antipsychotic-Induced Weight Gain: An Analysis of Two Clinical Trials
- Dongyu Kang,
- Dongyu Kang,
- Dongyu Kang,
- Dongyu Kang,
- Dongyu Kang,
- Zhihui Jing,
- Zhihui Jing,
- Zhihui Jing,
- Zhihui Jing,
- Zhihui Jing,
- Ranran Li,
- Ranran Li,
- Ranran Li,
- Ranran Li,
- Ranran Li,
- Gangrui Hei,
- Gangrui Hei,
- Gangrui Hei,
- Gangrui Hei,
- Gangrui Hei,
- Tiannan Shao,
- Tiannan Shao,
- Tiannan Shao,
- Tiannan Shao,
- Tiannan Shao,
- Li Li,
- Li Li,
- Li Li,
- Li Li,
- Li Li,
- Mengxi Sun,
- Mengxi Sun,
- Mengxi Sun,
- Mengxi Sun,
- Mengxi Sun,
- Ye Yang,
- Ye Yang,
- Ye Yang,
- Ye Yang,
- Ye Yang,
- Ying Wang,
- Ying Wang,
- Ying Wang,
- Ying Wang,
- Ying Wang,
- Xiaoyi Wang,
- Xiaoyi Wang,
- Xiaoyi Wang,
- Xiaoyi Wang,
- Xiaoyi Wang,
- Yujun Long,
- Yujun Long,
- Yujun Long,
- Yujun Long,
- Yujun Long,
- Xiansheng Huang,
- Renrong Wu,
- Renrong Wu,
- Renrong Wu,
- Renrong Wu,
- Renrong Wu,
- Renrong Wu
Affiliations
- Dongyu Kang
- Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, China
- Dongyu Kang
- Mental Health Institute of the Second Xiangya Hospital, Central South University, Changsha, China
- Dongyu Kang
- The China National Clinical Research Center for Mental Health Disorders, Changsha, China
- Dongyu Kang
- National Technology Institute of Psychiatry, Changsha, China
- Dongyu Kang
- Key Laboratory of Psychiatry and Mental Health of Hunan Province, Changsha, China
- Zhihui Jing
- Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, China
- Zhihui Jing
- Mental Health Institute of the Second Xiangya Hospital, Central South University, Changsha, China
- Zhihui Jing
- The China National Clinical Research Center for Mental Health Disorders, Changsha, China
- Zhihui Jing
- National Technology Institute of Psychiatry, Changsha, China
- Zhihui Jing
- Key Laboratory of Psychiatry and Mental Health of Hunan Province, Changsha, China
- Ranran Li
- Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, China
- Ranran Li
- Mental Health Institute of the Second Xiangya Hospital, Central South University, Changsha, China
- Ranran Li
- The China National Clinical Research Center for Mental Health Disorders, Changsha, China
- Ranran Li
- National Technology Institute of Psychiatry, Changsha, China
- Ranran Li
- Key Laboratory of Psychiatry and Mental Health of Hunan Province, Changsha, China
- Gangrui Hei
- Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, China
- Gangrui Hei
- Mental Health Institute of the Second Xiangya Hospital, Central South University, Changsha, China
- Gangrui Hei
- The China National Clinical Research Center for Mental Health Disorders, Changsha, China
- Gangrui Hei
- National Technology Institute of Psychiatry, Changsha, China
- Gangrui Hei
- Key Laboratory of Psychiatry and Mental Health of Hunan Province, Changsha, China
- Tiannan Shao
- Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, China
- Tiannan Shao
- Mental Health Institute of the Second Xiangya Hospital, Central South University, Changsha, China
- Tiannan Shao
- The China National Clinical Research Center for Mental Health Disorders, Changsha, China
- Tiannan Shao
- National Technology Institute of Psychiatry, Changsha, China
- Tiannan Shao
- Key Laboratory of Psychiatry and Mental Health of Hunan Province, Changsha, China
- Li Li
- Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, China
- Li Li
- Mental Health Institute of the Second Xiangya Hospital, Central South University, Changsha, China
- Li Li
- The China National Clinical Research Center for Mental Health Disorders, Changsha, China
- Li Li
- National Technology Institute of Psychiatry, Changsha, China
- Li Li
- Key Laboratory of Psychiatry and Mental Health of Hunan Province, Changsha, China
- Mengxi Sun
- Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, China
- Mengxi Sun
- Mental Health Institute of the Second Xiangya Hospital, Central South University, Changsha, China
- Mengxi Sun
- The China National Clinical Research Center for Mental Health Disorders, Changsha, China
- Mengxi Sun
- National Technology Institute of Psychiatry, Changsha, China
- Mengxi Sun
- Key Laboratory of Psychiatry and Mental Health of Hunan Province, Changsha, China
- Ye Yang
- Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, China
- Ye Yang
- Mental Health Institute of the Second Xiangya Hospital, Central South University, Changsha, China
- Ye Yang
- The China National Clinical Research Center for Mental Health Disorders, Changsha, China
- Ye Yang
- National Technology Institute of Psychiatry, Changsha, China
- Ye Yang
- Key Laboratory of Psychiatry and Mental Health of Hunan Province, Changsha, China
- Ying Wang
- Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, China
- Ying Wang
- Mental Health Institute of the Second Xiangya Hospital, Central South University, Changsha, China
- Ying Wang
- The China National Clinical Research Center for Mental Health Disorders, Changsha, China
- Ying Wang
- National Technology Institute of Psychiatry, Changsha, China
- Ying Wang
- Key Laboratory of Psychiatry and Mental Health of Hunan Province, Changsha, China
- Xiaoyi Wang
- Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, China
- Xiaoyi Wang
- Mental Health Institute of the Second Xiangya Hospital, Central South University, Changsha, China
- Xiaoyi Wang
- The China National Clinical Research Center for Mental Health Disorders, Changsha, China
- Xiaoyi Wang
- National Technology Institute of Psychiatry, Changsha, China
- Xiaoyi Wang
- Key Laboratory of Psychiatry and Mental Health of Hunan Province, Changsha, China
- Yujun Long
- Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, China
- Yujun Long
- Mental Health Institute of the Second Xiangya Hospital, Central South University, Changsha, China
- Yujun Long
- The China National Clinical Research Center for Mental Health Disorders, Changsha, China
- Yujun Long
- National Technology Institute of Psychiatry, Changsha, China
- Yujun Long
- Key Laboratory of Psychiatry and Mental Health of Hunan Province, Changsha, China
- Xiansheng Huang
- Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, China
- Renrong Wu
- Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, China
- Renrong Wu
- Mental Health Institute of the Second Xiangya Hospital, Central South University, Changsha, China
- Renrong Wu
- The China National Clinical Research Center for Mental Health Disorders, Changsha, China
- Renrong Wu
- National Technology Institute of Psychiatry, Changsha, China
- Renrong Wu
- Key Laboratory of Psychiatry and Mental Health of Hunan Province, Changsha, China
- Renrong Wu
- Shanghai Institute for Biological Science, Chinese Academy of Sciences, Shanghai, China
- DOI
- https://doi.org/10.3389/fpsyt.2018.00620
- Journal volume & issue
-
Vol. 9
Abstract
Antipsychotic-induced weight gain is one of the most common adverse effects of antipsychotic treatment. However, there are no well-established interventions for the weight gain yet. In this study, we pooled the data from two clinical trials, which were originally examining the efficacy of betahistine and the efficacy of metformin in treating antipsychotic-induced weight gain and insulin resistance. A total of 67 people with schizophrenia or bipolar disorder treated with antipsychotics were assigned to 36 mg day−1 betahistine (n = 13) or 1,000 mg day−1 metformin (n = 25) or placebo (n = 29) treatment for 12 weeks, with evaluation at baseline and week 12. The primary outcome was the body mass index (BMI). After treatment, metformin group had a mean decrease in BMI of 1.46 ± 0.14 (p < 0.001) and insulin resistance index (IRI) of 4.30 ± 2.02 (p < 0.001). The betahistine group had no significant alteration in BMI or IRI. However, placebo group had a mean increase in BMI of 1.27 ± 0.77 (p < 0.001) and IRI of 0.45 ± 0.86 (p < 0.001). Between the two treatment groups, metformin significantly decreased weight, BMI, fasting glucose, insulin level, and IRI but not waist circumference when compared with betahistine. Moreover, metformin significantly decreased weight, BMI, waist circumference, fasting glucose, insulin level, and IRI when compared with placebo, whereas betahistine significantly decreased body weight, waist circumference, BMI, insulin level, and IRI but not fasting glucose when compared with placebo. In this study, we found that both metformin treatment and betahistine treatment were efficacious in improving antipsychotic-induced weight gain and insulin resistance, and metformin was more efficacious in preventing and revising the weight gain induced by antipsychotics.Clinical Trial Registration:www.ClinicalTrials.gov, NCT00451399(Study 1), NCT00709202(Study 2)
Keywords
